The results showed that high expression of PFDN4 with doxorubicin (p = 0.0003701), paclitaxel (p = 0.001294) and cyclophosphamide (p = 0.003080) was significantly associated with survival rate in breast invasive carcinoma, but the other drugs were not. The gene discussed is PFDN4; the disease is invasive breast carcinoma.